Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
13 Noviembre 2023 - 6:00AM
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage
biotechnology company committed to discovering and delivering the
next generation of precision cancer medicines, today announced that
two abstracts have been selected for poster presentations at the
Society for Neuro-Oncology (SNO) 28th Annual Meeting taking place
November 15-19, 2023, in Vancouver, Canada.
“As we advance TNG908 and TNG462, our two
MTA-cooperative PRMT5 inhibitors, in phase 1/2 clinical trials, we
are pleased to share preclinical data at SNO that affirm their
potential as new therapies for patients with MTAP-deleted cancers,
including glioblastoma and malignant peripheral nerve sheath
tumors,” said Barbara Weber, M.D., President and Chief Executive
Officer of Tango Therapeutics. “TNG908 demonstrates strong
antitumor activity in MTAP-deleted glioblastoma models.
Additionally, data from preclinical malignant peripheral nerve
sheath tumor models evaluating TNG908 and TNG462 demonstrate
efficacy at well-tolerated doses. TNG462 is potentially
best-in-class. Dose escalation of TNG908 and TNG462 in phase 1/2
trials is ongoing.”
Abstracts accepted for poster
presentation
Title: TNG908, a brain-penetrant
MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical
MTAP-deleted models including glioblastomaPoster
#: DDDR-33Presenter: Minjie Zhang, Ph.D.,
Associate Director, Pharmacology, Tango TherapeuticsDate
and Time: Friday, November 17, 2023; 7:30 – 9:30 p.m.
PT
- Glioblastoma (GBM), the most common malignant primary brain
tumor in adults, has a poor prognosis and represents a significant
unmet need for more effective therapies. TNG908, a clinical stage
MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted
solid tumors, is shown to be brain penetrant and drives strong
antitumor activity in preclinical models of MTAP-deleted GBM.
Title: MTA-cooperative PRMT5
inhibitors are efficacious in MTAP-deleted malignant peripheral
nerve sheath tumor modelsPoster #:
EXTH-63Presenter: Xiaochun Zhang, M.D., Staff
Scientist, Hirbe Lab, Washington University School of Medicine in
St. LouisDate and Time: Friday, November 17, 2023;
7:30 – 9:30 p.m. PT
- Malignant peripheral nerve sheath tumors (MPNSTs) are highly
aggressive sarcomas with limited treatment options and poor
survival rates. The clinical stage MTA-cooperative PRMT5 inhibitors
TNG908 and TNG462 are efficacious in MPNST preclinical models and
represent potential new therapeutic strategies for patients with
MTAP-deleted MPNST.
Abstract titles, presentation information and text
are currently available to the public in the 2023 abstract
supplement to SNO’s official journal, Neuro-Oncology.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage
biotechnology company dedicated to discovering novel drug targets
and delivering the next generation of precision medicine for the
treatment of cancer. Using an approach that starts and ends with
patients, Tango leverages the genetic principle of synthetic
lethality to discover and develop therapies that take aim at
critical targets in cancer. This includes expanding the universe of
precision oncology targets into novel areas such as tumor
suppressor gene loss and their contribution to the ability of
cancer cells to evade immune cell killing. For more information,
please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events, Tango’s future operating
performance and goals, the anticipated benefits of therapies and
combination therapies (that include a Tango pipeline product),
expectations, beliefs and development objectives for Tango’s
product pipeline and clinical trials. In some cases, you can
identify forward-looking statements by terminology such as “may”,
“should”, “expect”, “intend”, “will”, “goal”, “estimate”,
“anticipate”, “believe”, “committed” “predict”, “designed,”
“potential” or “continue”, or the negatives of these terms or
variations of them or similar terminology. For example, implicit or
explicit statements concerning the following include or constitute
forward-looking statements: the data presented at SNO supports the
ongoing clinical development of the Company’s PRMT5 inhibitors for
the treatment of MTAP-deleted cancers; the Company is committed to
discovering and delivering the next generation of precision cancer
medicines; the preclinical data presented at SNO affirm TNG908’s
and TNG462’s potential as new therapies for patients for
MTAP-deleted cancers, including glioblastoma and malignant
peripheral nerve sheath tumors; TNG462 is potentially
best-in-class; dose escalation of TNG908 and TNG462 is ongoing;
TNG908 and TNG462 represent potential new therapeutic strategies
for patients with MTAP-deleted MPNST; the expected timing of: (i)
development candidate declaration for certain targets, (ii)
initiating IND-enabling studies; (iii) filing INDs; (iv) clinical
trial initiation and (v) disclosing initial, interim and final
clinical trial results; and the expected benefits of the Company's
development candidates and other product candidates. Such
forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially
from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by Tango and its
management, are inherently uncertain. New risks and uncertainties
may emerge from time to time, and it is not possible to predict all
risks and uncertainties. Factors that may cause actual results to
differ materially from current expectations include, but are not
limited to: benefits of product candidates seen in preclinical
analyses may not be evident when tested in later pre-clinical
studies or in clinical trials or when used in broader patient
populations (if approved for commercial sale); Tango has limited
experience conducting clinical trials (and will rely on a third
party to operate its clinical trials) and may not be able to
commence the clinical trial (including opening clinical trial
sites, dosing the first patient, and enrolling and dosing an
adequate number of clinical trial participants) when expected, may
not be able to continue dose escalation on anticipated timelines,
and may not generate results (including final or initial safety,
efficacy data and proof-of-mechanism and proof-of-concept) in the
anticipated timeframe (or at all); Tango’s pipeline products may
not be safe and/or effective in humans; Tango has a limited
operating history and has not generated any revenue to date from
product sales, and may never become profitable; other companies may
be able to identify and develop product candidates more quickly
than the Company and commercially introduce the product prior to
the Company; the Company’s proprietary discovery platform is novel
and may not identify any synthetic lethal targets for future
development; the Company may not be able to identify development
candidates on the schedule it anticipates due to technical,
financial or other reasons; the Company may not be able to file
INDs for development candidates on time, or at all, due to
technical or financial reasons or otherwise; the Company may
utilize cash resources more quickly than anticipated; Tango will
need to raise capital in the future and if we are unable to raise
capital when needed or on attractive terms, we would be forced to
delay, scale back or discontinue some of our development programs
or future commercialization efforts (which may delay filing of
INDs, dosing patients, reporting clinical trial results and filing
new drug applications); Tango’s approach to the discovery and
development of product candidates is novel and unproven, which
makes it difficult to predict the time, cost of development, and
likelihood of successfully developing any products; Tango may not
identify or discover additional product candidates or may expend
limited resources to pursue a particular product candidate or
indication and fail to capitalize on product candidates or
indications that may be more profitable or for which there is a
greater likelihood of success; the Company’s product candidates may
cause adverse or other undesirable side effects (or may not show
requisite efficacy) that could, among other things, delay or
prevent regulatory approval; our dependence on third parties for
conducting clinical trials and producing drug product; our ability
to obtain and maintain patent and other intellectual property
protection for our technology and product candidates or the scope
of intellectual property protection obtained is not sufficiently
broad; and delays and other impacts on product development and
clinical trials from the COVID-19 pandemic. Additional information
concerning risks, uncertainties and assumptions can be found in
Tango’s filings with the SEC, including the risk factors referenced
in Tango’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2022, as supplemented and/or modified by its most
recent Quarterly Report on Form 10-Q. You should not place undue
reliance on forward-looking statements in this presentation, which
speak only as of the date they are made and are qualified in their
entirety by reference to the cautionary statements herein. Tango
specifically disclaims any duty to update these forward-looking
statements.
Investor Contact:Sam Martin/Andrew
VulisArgot Partnerstango@argotpartners.com
Media Contact:Amanda Brown
GalgaySVP, Corporate Communications, Tango
Therapeuticsmedia@tangotx.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfica de Acción Histórica
De May 2023 a May 2024